Comparative Pharmacology
Head-to-head clinical analysis: TENSILON versus TENSILON PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TENSILON versus TENSILON PRESERVATIVE FREE.
TENSILON vs TENSILON PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetylcholinesterase inhibitor; increases acetylcholine concentration at cholinergic synapses by inhibiting hydrolysis of acetylcholine.
Edrophonium chloride is a reversible acetylcholinesterase inhibitor. It binds to the anionic site of acetylcholinesterase, preventing hydrolysis of acetylcholine and thereby increasing acetylcholine concentrations at the neuromuscular junction and in the autonomic nervous system.
2-10 mg intravenously over 15-30 seconds, repeated every 2-5 minutes as needed for diagnosis of myasthenia gravis, up to a total of 10 mg; for reversal of neuromuscular blockade: 10-20 mg intravenously slowly after atropine.
2 mg intravenous test dose; if tolerated, 8 mg IV push over 1-2 minutes. Diagnostic dose may be repeated after 1 hour.
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours in adults; prolonged in renal impairment.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In renal impairment, half-life may be prolonged (up to 8-10 hours in severe renal failure), necessitating dose adjustment.
Renal: >90% unchanged via tubular secretion and glomerular filtration; biliary/fecal: <5%.
Primarily renal excretion as unchanged drug and metabolites; approximately 80-90% excreted in urine within 24 hours, with about 30% as unchanged edrophonium. Biliary/fecal elimination accounts for <10%.
Category C
Category C
Cholinesterase inhibitor
Cholinesterase inhibitor